Method for treating inflammatory brain disorders and traumatic brain injury

• US 10,272,107 B2
• Filed: 09/05/2017
• Issued: 04/30/2019
• Est. Priority Date: 09/05/2017
• Status: Active Grant

• Current Assignee: Russ IP Holding Group LLC
• Original Assignee: Metabolic Therapy Inc.
• Inventors: Russell, Kenneth O.
• Primary Examiner(s): Blanchard, David J
• Assistant Examiner(s): Coughlin, Daniel F.
• Application Number:
  US15/695,188
• Publication Number:
  US 20190070218A1
• Time in Patent Office: 602 Days
• Field of Search: None
• CPC Class Codes: A61K 31/51 Thiamines, e.g. vitamin B1
• CPC Class Codes: A61K 31/593 9,10-Secocholestane derivatives, e.g. cholecalciferol, i.e. vitamin D3
• CPC Class Codes: A61K 31/714 Cobalamins, e.g. cyanocobalamin, i.e. vitamin B12
• CPC Class Codes: A61K 33/06 Aluminium, calcium or magnesium; Compounds thereof , e.g. clay
• CPC Class Codes: A61K 33/24 Heavy metals; Compounds thereof
• CPC Class Codes: A61K 45/06 Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
• CPC Class Codes: A61P 25/28 for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Abstract

The present invention provides methods for treating an inflammatory brain disease and for treating a traumatic brain injury in a human having an inflammatory component applying transdermal pharmaceutical compositions comprising chromium, magnesium, and thiamine as active ingredient compounds that act as neuroprotective iron chelators and brain glucose-uptake enhancement that are suitable for the treatment of traumatic brain injury. The invention further relates to methods of delivering the pharmaceutical compositions that target the brain and/or central nervous system certain novel iron chelators of the type described in the specification.

Claims

1. A method for treating Alzheimer'"'"'s disease, the method comprising:

transdermally administering a pharmaceutical composition to the human body in need thereof, wherein the pharmaceutical composition comprising;

from about 0.000422% to about 0.00169% by weight of chromium chloride;

from about 0.676% to about 2.705% by weight of magnesium sulfate; and

therapeutically effective amount of thiamine mononitrate, vitamin B12, and vitamin D3, wherein the percentage by weight is relative to the total weight of the composition.

2. The method according to claim 1, wherein the method further comprises reducing infiltration of a population of a mononuclear cell into the brain of the subject.

3. The method according to claim 1 comprising administering said composition for at least two (2) weeks.

4. The method of claim 1, comprising administering said composition for at least four (4) weeks.

5. The method of claim 1, comprising administering said composition for at least six (6) weeks.

6. The method of claim 1, comprising administering said composition at least once every day.

7. The method of claim 1, wherein said composition is selected from a group consisting of lotion, gel, and any combination thereof.